As Jounce’s Vopratelimab Fails, Door Opens For LILRB2 Inhibitor JTX-8064

 
• By Alaric DeArment
  
Announcing SELECT's failure gives Jounce the chance to shift gears to JTX-8064 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D